Für die Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) stehen inzwischen mehrere moderne Wirkstoffe zur Verfügung. Sie verdrängen zunehmend die aufgrund mangelnder Alternativen lange Jahre üblichen sekundären Hormonmanipulationen, denn neuere Substanzen konnten - im Gegensatz zu den konventionellen antihormonellen Therapien - das Überleben in Phase-III-Studien verlängern. So ist der Beginn der mCRPC-Therapie gemäß Leitlinie der European Association of Urology in den letzten Jahren im Krankheitsverlauf nach vorne gerückt. Für den Androgen-Biosynthese-Inhibitor Abirateronacetat, einen dieser modernen Wirkstoffe, liefern mehrere Analysen zusätzliche Hinweise, wann die Behandlung begonnen werden könnte.

Keywords:
Prostatakarzinom, mCRPC, Kastrationsresistenz, ­The­rapiebeginn, Abirateronacetat
1.
Mottet N, Bellmunt J, Briers E, et al: Guidelines on Prostate Cancer. European Association of Urology - Update 2016. http://uroweb.org/guideline/prostate-cancer/ (letzter Zugriff am 11.01.2016).
2.
Heidenreich A, Bastian PJ, Bellmunt J, et al: Guidelines on Prostate Cancer. European Association of Urology - Update March 2013. http://uroweb.org/guideline/prostate-cancer/?type=archive (letzter Zugriff am 11.01.2016).
3.
Mottet N, Bastian PJ, Bellmunt J, et al: Guidelines on Prostate Cancer. European Association of Urology - Update April 2014. http://uroweb.org/guideline/prostate-cancer/?type=archive (letzter Zugriff am 06.09.2016).
4.
Miller K, Carles J, Gschwend JE, et al: The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRCP): stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS). Eur Urol Suppl 2016;15:e775-e775a.
5.
Fizazi K, Flaig TW, Stöckle M, et al: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol 2016;27:699-705.
6.
Ryan CJ, Londhe A, Molina A, et al: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302. J Clin Oncol 2013;31(suppl):abstr 5010.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.